Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Cash from Operations (2019 - 2025)

Pulmonx (LUNG) has disclosed Cash from Operations for 7 consecutive years, with 8162000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 13.36% to 8162000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 31992000.0, a 3.64% increase, with the full-year FY2024 number at 31500000.0, up 16.22% from a year prior.
  • Cash from Operations was 8162000.0 for Q3 2025 at Pulmonx, down from 3908000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 3908000.0 in Q2 2025 to a low of 15026000.0 in Q1 2022.
  • A 5-year average of 9519105.26 and a median of 9574000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 65.86% in 2021, then skyrocketed 32.62% in 2025.
  • Pulmonx's Cash from Operations stood at 10711000.0 in 2021, then increased by 8.45% to 9806000.0 in 2022, then increased by 14.34% to 8400000.0 in 2023, then grew by 20.24% to 6700000.0 in 2024, then dropped by 21.82% to 8162000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Cash from Operations are 8162000.0 (Q3 2025), 3908000.0 (Q2 2025), and 13222000.0 (Q1 2025).